Skip to main content
. Author manuscript; available in PMC: 2018 Mar 28.
Published in final edited form as: Cancer Lett. 2016 Dec 23;389:33–40. doi: 10.1016/j.canlet.2016.12.020

Fig 1.

Fig 1

The sGC stimulators synergize with cisplatin to reduce the viability of HNSCC cells. The HNSCC cell lines UMSCC-1 (UM1) (A), CAL27 (B) and UMSCC-47 (UM47) (C) were treated with increasing doses of YC-1 (left panels) or BAY (right panels) alone, or together with the indicated doses of cisplatin for 72h. Cell viability was determined by the MTT assay. Each value is a mean±SEM of 6 replicates.